{"organizations": [], "uuid": "5472eff11467bf51d3d7c2d2004e80dccf0f8dc1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180116.html", "section_title": "Archive News &amp; Video for Tuesday, 16 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-armo-biosciences-sees-ipo-of-up-to/brief-armo-biosciences-sees-ipo-of-up-to-6-7-mln-shares-of-common-stock-estimated-ipo-price-between-14-and-16-shr-idUSFWN1PB0SP", "country": "US", "domain_rank": 408, "title": "BRIEF-ARMO Biosciences Sees IPO Of Up To 6.7 Mln Shares Of Common Stock, Estimated IPO Price Between $14 And $16/Shr", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.002, "site_type": "news", "published": "2018-01-16T21:15:00.000+02:00", "replies_count": 0, "uuid": "5472eff11467bf51d3d7c2d2004e80dccf0f8dc1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-armo-biosciences-sees-ipo-of-up-to/brief-armo-biosciences-sees-ipo-of-up-to-6-7-mln-shares-of-common-stock-estimated-ipo-price-between-14-and-16-shr-idUSFWN1PB0SP", "ord_in_thread": 0, "title": "BRIEF-ARMO Biosciences Sees IPO Of Up To 6.7 Mln Shares Of Common Stock, Estimated IPO Price Between $14 And $16/Shr", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 16 (Reuters) -\n* ARMO BIOSCIENCES INC SEES IPO OF UP TO 6.7 MILLION SHARES OF COMMON STOCK AND ESTIMATED IPO PRICE BETWEEN $14.00 AND $16.00 PER SHARE - SEC FILING\n* ARMO BIOSCIENCES - INTENDS TO USE ABOUT $35 MILLION OF IPO PROCEEDS TO FUND DEVELOPMENT OF AM0010 FOR TREATMENT OF PDAC, INCLUDING PHASE 3 CLINICAL TRIAL\n* ARMO BIOSCIENCES - INTENDS TO USE ABOUT $35 MILLION OF IPO PROCEEDS TO FUND TWO PLANNED PHASE 2B CLINICAL TRIALS IN NSCLC Source text: ( bit.ly/2FGsF7g )\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2FGsF7g"], "published": "2018-01-16T21:15:00.000+02:00", "crawled": "2018-01-17T19:44:51.004+02:00", "highlightTitle": ""}